Moreover, some of these genes are target of current clinical trials for other types of cancer, such as RET for non-small cell lung cancer, RUNX1 for leukemia, and XIAP for pancreatic and breast cancers (http://clinicaltrials.gov, https://www.clinicaltrialsregister.eu), so they could be interesting targets also for colorectal cancer therapy. This evidence concerns the gene RUNX1 and breast carcinoma.